Early-Cancer Detection Company iCareDx Announces Corporate Name Change To Acuamark Diagnostics
iCareDx, Inc., a biotechnology company focused on blood-based early detection of cancer, today announced that it has changed its name to Acuamark Diagnostics, Inc. In conjunction with its corporate name change, the Company’s website will be available at www.acuamarkdx.com .
Globally, over 22,000 people die of cancer each day. When cancer is detected at the early stages, survival rates are generally still high. Finding cancer early with an accurate, convenient and affordable technology, and attacking it early, can vastly reduce cancer deaths, and substantially lower cancer-related healthcare expenditures.
Dr. Bernard Peperstraete, CEO of Acuamark Diagnostics, Inc. (formerly iCareDx, Inc.) stated, "Our team is excited to re-brand the Company as Acuamark Diagnostics. The name “Acuamark” incorporates several elements that play to the essence of our corporate mission, and well embodies the progress we have made towards developing an accurate diagnostic screening technology to detect low-abundance tumor markers from liquids at the earliest stages of cancer.”
Dr. Francis Barany, PhD, Professor of Microbiology and Immunology at the Weill Cornell Medicine, and lead inventor of Acuamark Diagnostics’ molecular detection technologies, adds: “In addition, the name Acuamark Diagnostics is a reflection that each cancer leaves a unique watermark in our bodies, and as with a watermark, it is barely visible, requiring one to see it in a different light.”
About Acuamark Diagnostics Inc.
Acuamark Diagnostics is a biotechnology company focused on developing screening tests technologies for blood-based early detection of cancer. Acuamark Diagnostics' technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is Acuamark Diagnostics’ mission to contribute to the global battle against cancer by detecting and attacking cancer through high-precision, early detection.
Acuamark Diagnostics, Inc.
Bernard Peperstraete, MD
Chief Executive Officer
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CELLTRION15.12.2017 23:15 | pressemeddelelse
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar
TAKEDA15.12.2017 13:36 | pressemeddelelse
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
TWISPAY15.12.2017 13:23 | pressemeddelelse
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards
PEACE-FORUM15.12.2017 12:40 | pressemeddelelse
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum
CA-KENNEDY-WILSON15.12.2017 12:02 | pressemeddelelse
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million
NV-NAC-FOUNDATION15.12.2017 10:02 | pressemeddelelse
AML BitCoin Enters Phase II of ICO
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum